Following the 1995 meta-analysis on the role of postoperative chemotherapy in NSCLC,
many randomized controlled trials (RCTs) have evaluated the effect of adjuvant cisplatin …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Objective: Chemotherapy of stage IIIA non-small cell lung cancer (NSCLC) using second
generation, cisplatin-based combinations has shown to improve the results; however, the …

Introduction: Neoadjuvant therapy in patients with Stage IIIA NSCLC is associated with a 50–
70% resection rate and a 3–5 year survival of 20–32%, but few trials have required …

Background On the basis of a previous meta-analysis, the International Adjuvant Lung
Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy …

Lung cancer is still the leading cause of cancer death worldwide, and non-small cell lung
cancer accounts for 80% to 85% of all lung cancer cases. Surgery, radiation therapy, and …

Introduction: Adjuvant platinum based chemotherapy is accepted as standard of care in
stage II and III non-small cell lung cancer (NSCLC) patients and is often considered in …

PURPOSE This phase II trial was designed to evaluate the feasibility, toxicity, response
rates, and survival for neoadjuvant chemotherapy and radiotherapy (RT) followed by …

The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing
population and introduction of screening for high-risk individuals. Optimal management …

Surgical therapy for stage III non-small cell lung cancer (NSCLC) has not resulted in
substantial long-term survival. Neoadjuvant treatment programs that could down-stage the …